Name of journal: World Journal of Gastrointestinal Oncology
Manuscript NO: 65638
Title: Atezolizumab plus Bevacizumab versus Sorafenib or Atezolizumab alone for Unresectable Hepatocellular Carcinoma: Systematic Review
Reviewer’s code: 01798570
Position: Editorial Board
Academic degree: MD
Professional title: Full Professor, Professor
Reviewer’s Country/Territory: Turkey
Author’s Country/Territory: Italy
Manuscript submission date: 2021-03-12
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-04-16 18:38
Reviewer performed review: 2021-04-18 12:10
Review time: 1 Day and 17 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>[ Y] Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ Y] Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>[ Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [ Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>statements</td>
<td>Conflicts-of-Interest: [ ] Yes</td>
<td>[ Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
Finding more than four studies could make the comparison more exclusive.
Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 65638

Title: Atezolizumab plus Bevacizumab versus Sorafenib or Atezolizumab alone for Unresectable Hepatocellular Carcinoma: Systematic Review

Reviewer’s code: 03475142

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: Italy

Manuscript submission date: 2021-03-12

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-15 10:54

Reviewer performed review: 2021-04-24 09:46

Review time: 8 Days and 22 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[Y] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[Y] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Peer-reviewer statements: Peer-Review: [Y] Anonymous | [ ] Onymous
Conflicts-of-Interest: [ ] Yes | [Y] No
SPECIFIC COMMENTS TO AUTHORS
The manuscript was reviewed for publication in the journal. The manuscript was designed to compare the efficacy and safety of combination immunogenic chemotherapy of atezolizumab and bevacizumab as first-line therapy as opposed to sorafenib and atezolizumab monotherapies, for patients with advanced HCC. The results obtained indicated that treatment of HCC with atezolizumab-bevacizumab is effective in improving survival in patients with unresectable HCC. It is the reviewer’s opinion that the review is interesting and that the manuscript is easy to follow for the readers. However, it appears that there are a couple of concerns in the manuscript. 1) As the authors have discussed, this systematic review may be judged inadequate to provide strong recommendations due to the small number of included RCTs, two completed trials and two ongoing trials. This systematic review appears to be sort of premature. 2) The authors should emphasize the value of this review in more detail, compared to just reading the papers of two completed trials and two ongoing trials.